Company news

Climb Bio, Inc. news in 2026

Climb Bio, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates

November 5, 2026

Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition

November 4, 2026

Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference

November 2, 2026

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

October 24, 2026

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

October 23, 2026

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

October 2, 2026

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

September 3, 2026

Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

June 11, 2026

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

June 4, 2026

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

May 26, 2026

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

May 14, 2026

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

May 7, 2026

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

May 5, 2026

Climb Bio, Inc. Announces $110.0 Million Private Placement

April 28, 2026

Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026

April 7, 2026

Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy

April 6, 2026

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

March 5, 2026

Climb Bio to Present at Upcoming Investor Conferences

February 5, 2026

Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

January 8, 2026

Decks in 2026